William Blair Issues Optimistic Forecast for Harrow Earnings

Key Points

• William Blair raised Harrow's Q3 2025 earnings estimate from $0.08 to $0.13 per share and maintains an "Outperform" rating on the stock.
• Harrow stock has an average rating of "Buy" with a consensus price target of $64.67, supported by multiple analysts including HC Wainwright and Cantor Fitzgerald.
• The company recently reported $0.24 earnings per share, significantly exceeding analyst expectations, while also generating revenue of $63.74 million.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Stock analysts at William Blair raised their Q3 2025 earnings per share estimates for Harrow in a report issued on Tuesday, August 12th. William Blair analyst L. Hanbury-Brown now expects that the company will post earnings of $0.13 per share for the quarter, up from their prior estimate of $0.08. William Blair has a "Outperform" rating on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow's Q4 2025 earnings at $0.07 EPS, FY2025 earnings at $0.22 EPS and FY2026 earnings at $1.37 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The firm had revenue of $63.74 million during the quarter, compared to analysts' expectations of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

A number of other equities analysts have also weighed in on the stock. HC Wainwright upped their target price on shares of Harrow from $60.00 to $64.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. BTIG Research boosted their target price on Harrow from $62.00 to $63.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Cantor Fitzgerald initiated coverage on shares of Harrow in a report on Friday, July 11th. They issued an "overweight" rating and a $76.00 price target on the stock. Finally, Zacks Research upgraded shares of Harrow from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $64.67.

Harrow Stock Down 0.2%

NASDAQ HROW traded down $0.09 on Friday, reaching $38.23. The company had a trading volume of 606,526 shares, compared to its average volume of 483,640. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -152.92 and a beta of 0.41. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. Harrow has a 1-year low of $20.85 and a 1-year high of $59.23. The company's fifty day moving average is $33.34 and its 200-day moving average is $28.92.

Hedge Funds Weigh In On Harrow

A number of institutional investors have recently added to or reduced their stakes in the stock. Braidwell LP raised its position in Harrow by 106.3% during the 4th quarter. Braidwell LP now owns 907,039 shares of the company's stock worth $30,431,000 after purchasing an additional 467,401 shares during the last quarter. Voya Investment Management LLC raised its position in Harrow by 4,035.5% during the 1st quarter. Voya Investment Management LLC now owns 381,461 shares of the company's stock worth $10,147,000 after purchasing an additional 372,237 shares during the last quarter. Diametric Capital LP bought a new position in Harrow during the 2nd quarter worth $4,748,000. Bank of America Corp DE raised its position in Harrow by 266.8% during the 2nd quarter. Bank of America Corp DE now owns 213,448 shares of the company's stock worth $6,519,000 after purchasing an additional 155,258 shares during the last quarter. Finally, Divisadero Street Capital Management LP bought a new position in Harrow during the 2nd quarter worth $4,293,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.